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In recent years, the etiology of human disease has greatly improved with the inclusion of 
epigenetic mechanisms, in particular as a common link between environment and disease. 
However, for most diseases we lack a detailed interpretation of the epigenetic regulatory pathways 
perturbed by environment and causal mechanisms. Here, we focus on recent findings elucidating 
nutrient-related epigenetic changes linked to obesity. We highlight studies demonstrating that 
obesity is a complex disease linked to disruption of epigenetically regulated metabolic pathways in 
the brain, adipose tissue and liver. These pathways regulate (1) homeostatic and hedonic eating 
behaviors (2) adipocyte differentiation and fat accumulation, and (3) energy expenditure. By 
compiling these data we illustrate that obesity-related phenotypes are repeatedly linked to 
disruption of critical epigenetic mechanisms that regulate of key metabolic genes. These data are 
supported by genetic mutation of key epigenetic regulators and many of the diet induced 
epigenetic mechanisms of obesity are also perturbed by exposure to environmental toxicants. 
Identifying similarly perturbed epigenetic mechanisms in multiple experimental models of obesity 
strengthens the translational applications of these findings. We also discuss many of the ongoing 
challenges to understanding the role of environmentally-induced epigenetic pathways in obesity 
and suggest future studies to elucidate these roles. This assessment illustrates our current 
understanding of molecular pathways of obesity that are susceptible to environmental perturbation 
via epigenetic mechanisms. Thus, it lays the groundwork for dissecting the complex interactions 
between diet, genes, and toxicants that contribute to obesity and obesity-related phenotypes.
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Environmental exposure contributes significantly to disease risk [1]. Accumulating evidence 
from dietary and genetic models of nutrient perturbation, links the disruption of critical 
metabolic pathways to development of disease. Obesity was recently classified as a disease 
with strong links to environmental exposures. According to the World Health Organization 
(WHO), worldwide over 600 million adults and 42 million children are obese, figures which 
have more than doubled since 1980. While obesity is most often associated with 
overconsumption of calories (overnutrition) combined with lowered energy expenditure, 
recent studies show that obesity is a highly complex disease with both causal and 
contributory links to metabolic dysfunction. Development of obesity is influenced by 
multiple pathways, including (1) hedonic and homeostatic eating behaviors that are directly 
regulated by the brain, (2) energy expenditure in tissues such as liver, fat and muscle (3) and 
changes in adiposity mediated by adipocyte differentiation and lipid accumulation in adipose 
tissues. Homeostatic eating is need-based and replenishes energy storage, while hedonic 
eating is reward-driven and motivated by desire for palatable food [2]. As a causal factor, 
obesity is linked to increased risk of diseases such as diabetes [3, 4], cardiovascular disease 
(CVD) [5–7], cancer [8–10], arthritis [11, 12], infertility [13, 14], and mental health 
disorders [15, 16]. Importantly, new studies show that many of these pathways are regulated 
by epigenetic mechanisms that are disrupted by environmental factors. Here, we compile 
these findings in order to highlight common mechanisms of epigenetic perturbation linked to 
obesity as potential targets for prevention, diagnoses or treatment.
Epigenetic machinery regulates gene expression by orchestrating the levels and interactive 
activity of highly conserved genomic processing including DNA methylation, post-
translational histone modification, and non-coding RNA activity [17]. In mammals, 
methylation at CpG dinucleotides to generate 5-methylcytosine (5mC) is catalyzed by DNA 
methyltransferases (DNMTs) including DNMT1, DNMT3A and DNMT3B. DNMT3A and 
DNMT3B enzymes mediate de novo DNA methylation primarily during embryonic 
development [18] while DNMT1 maintains DNA methylation states in all mitotically 
dividing cells [19]. Methylated DNA is often considered a primary epigenetic mark that can 
then be recognized and bound by methyl binding proteins. These include methyl CpG 
binding protein 2 (MECP2) to trigger subsequent epigenetic changes by histone modulators 
[20, 21]. The lysine residues of histone N-terminal tails within DNA bound nucleosomes are 
modified by methylation, acetylation, phosphorylation, ubiquitination, sumoylation and 
biotinylation [17, 22–24]. On the other hand, non-coding RNA include functionally distinct 
classes of untranslated RNA including micro RNA (miRNA), long noncoding RNA 
(IncRNA), piwi-interacting RNA (piRNA), and small nucleolar RNA (snoRNA) [25]. Of 
equal importance to the factors required to establish and maintain DNA and histone 
modifications and non-coding RNA levels and functions, are the factors required to erase or 
deplete these epigenetic states. This is required for the resetting or alteration of epigenetic 
programs necessary for reprogramming cell fate towards germline or somatic lineages and 
for cellular differentiation and response to environmental stimuli. These epigenetic erasers 
include histone demethylases and deacetylases and putative DNA demethylases. For 
example, the ten-eleven translocation (TET) proteins convert 5mC into 5-
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hydroxymethylcytosine (5hmC) but remain under investigation as to whether this is a 
functional modification or merely a step towards demethylation [26].
The role of epigenetic mechanisms in gene expression is defined by many factors including 
cellular or genomic location of the acting mechanism, the developmental timing of 
establishment/maintenance of the mechanism and co-regulation by multiple co-acting 
epigenetic mechanisms. Multiple mechanisms co-regulate different loci at different stages of 
development to establish, maintain or change the transcriptional outcome of the cell. Despite 
ongoing research to fully elucidate these concurrent mechanisms, some general functions 
have been assigned to commonly occurring epigenetic states. DNA hypermethylation at 
promoter regions is most often correlated with transcriptional repression, however 
hypermethylation at intra- or intergenic regions may reflect either an active or repressed 
state. Likewise, the transcriptional regulation of modified histones depends on the type of 
modification and the location of the lysine modified. For example, acetylated histones 
primarily mark actively transcribed regions while the function of methylated histones 
depends on the location of lysine residue, e.g. trimethylation of histone H3 lysine 9 
(H3K9me3) marks transcriptional repression and H3K4me3 are enriched around 
transcription start site of active genes [27]. On the other hand, non-coding RNA function is 
primarily determined by the sequence encoded, post-transcriptional processing and 
secondary structure of the RNA, cellular transport and target (RNA, DNA, or protein) of the 
non-coding RNA and can result in either upregulation or downregulation of the target at the 
transcriptional or posttranscriptional level [25].
Epigenetic regulatory mechanisms are reported to play a role in all of the obesity related 
pathways mentioned above, including food intake, energy expenditure and adiposity. Diet 
has been shown to play an important, albeit complex, role in determining these epigenetic 
states. Some dietary compounds act directly on epigenetic machinery while other nutrients 
act indirectly. For example, retinoid X receptors (RXRs), activated by vitamin A metabolite 
retinoid acid, regulate transcription in adipocytes by directly binding to promoters of histone 
modifier genes such as SET domain bifurcated 1 (Setdb1) and SET domain containing 
protein 8 (Setd8), both lysine methyltransferases [28–30]. On the other hand, intake of 
niacin and methyl donor nutrients such as folate and choline determine cellular availability 
of methyl groups and thus are proposed to act by limiting DNA and histone methylation 
reactions [31, 32].
There is a significant and growing body of work highlighting the role of epigenetic 
mechanisms in obesity. Here we focus on a few specific studies and well characterized 
pathways of obesity to elucidate the role of altered nutrient availability in causing obesity 
via epigenetic mechanisms. We also discuss a potential overlapping or aggregate role for 
nutrition in susceptibility to obesity linked to environmental pollutants since it is well known 
that diet can indeed alter the effect of toxic compounds. One example is the role of dietary 
calcium, vitamin D, iron, fat and phosphorus in inhibiting gastrointestinal lead absorption in 
the gastrointestinal tract (as reviewed in [33]). Another example is the role of diet-induced 
adiposity in influencing the availability of circulating toxicants via toxicant sequestration in 
adipose tissue. Studies show that body fat composition is inversely correlated with 
circulating plasma levels of lipophilic persistent organic pollutants (POPs) and rapid weight 
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loss is correlated with increased plasma levels of POPs [34–36]. Furthermore, nutrient 
availability can interfere with the levels of key enzymes required for toxicant metabolism. 
Such interactions influence metabolism required for toxicant inactivation and excretion [37–
41] and metabolism required for toxicant activation, thus altering toxicity [42–44]. For 
example, Cytochrome p450 (Cyp450) enzymes have been shown to play critical roles in 
metabolizing POPs [35, 45]. Cyp450 enzyme levels are altered by many nutrients including 
dietary protein [46, 47], fat [48], sugar [49], vitamin C [50, 51], vitamin E [39], folate[40], 
betaine [52], iodine and selenium [53]. These findings highlight the potential for aggregate 
effects of diet-toxicant interactions and offer the promise of dietary intervention of diseases 
related to toxicant exposure. In order to bring these research findings to practice and 
maximize public health benefits we must first understand more about the mechanisms 
responsible. Here, we focus on obesity because of the abundance of research available, but 
we hold the expectation that this paradigm likely applies to other environmentally based 
diseases.
2.1 Molecular pathways of obesity regulated by nutrition
2.1.1 Proopiomelanocortin methylation and epi-regulation of proopiomelanocortin neuron
Proopiomelanocortin is a precursor to several hormones related to appetite regulation, 
energy homeostasis, sexual behavior and various reward pathways. While it is expressed at 
high levels in the pituitary, it is also found in other cells/tissues primarily in other parts of 
the brain such as the hypothalamus, skin cells and reproductive systems, and relatively 
accurate levels can be measured in peripheral blood [54–56]. Proopiomelanocortin neurons 
are nerve cells in the arcuate nucleus of hypothalamus that express proopiomelanocortin 
protein. Hypothalamic proopiomelanocortin neurons inhibit satiety, thus altered 
proopiomelanocortin gene expression is most commonly associated with either obesity or 
underweight phenotypes although studies suggest there may be inverse relationships 
depending on the cell/tissue type where it is measured [56]. Generally, decreased 
hypothalamus expression of proopiomelanocortin or its downstream products is highly 
correlated with weight gain/obesity while increased expression is associated with weight 
loss [57–59].
Association studies have identified several SNPs in or near the proopiomelanocortin locus 
associated with weight related phenotypes [60–62]. There is also strong evidence of 
additional epigenetic regulation of both proopiomelanocortin expression via DNA 
methylation of two CpG islands within the gene promoter and body [56, 63]. Recent studies 
propose DNA methylation levels at the proopiomelanocortin promoter in cord blood serves 
as an important early predictive marker of metabolic syndrome later in life [64]. Despite the 
strong correlation between DNA methylation at proopiomelanocortin, gene expression and 
phenotypic variation, mechanisms of epigenetic regulation of proopiomelanocortin 
expression remain unclear. Most recently a study by Zhang and colleagues [65] use cultured 
cells to show that hypermethylation at the proopiomelanocortin promoter and within the 
binding site [66] for proximal specificity protein 1 (SP1), blocked formation of the SP1-
promoter complex required for activation of proopiomelanocortin. Interestingly, they also 
showed using a lactation-staged mouse model this aberrant methylation at the 
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proopiomelanocortin promoter is induced by maternal dietary supplementation of 
conjugated linoleic acids (CLAs). Similarly, the hypothalamic proopiomelanocortin SP1 cis-
element was hypermethylated in a neonatal overfeeding model induced by rearing rats in 
small litters. This caused a blunted response of proopiomelanocortin neurons to leptin 
signaling [67]. In contrast, both gestational and post-weaning high folate diet in a rat model 
resulted in hypomethylation of the proopiomelanocortin promoter in the hypothalamus of 
offspring, decreased food intake and lower weight [68]. Two separate studies examined the 
effects of a maternal high fat diet in a rat model and showed consistent results of 
hypermethylation at the hypothalamic proopiomelanocortin promoter associated with 
disrupted energy homeostasis leading to increased food intake and subsequent weight gain 
of exposed pups [69, 70]. Although limited in mechanistic potential, human studies 
seemingly mirror these effects and a recent study showed that caloric restriction induced 
weight gain or weight loss is associated with changes in proopiomelanocortin gene body 
methylation in leukocytes [71]. To further validate the importance of DNA methylation at 
the proopiomelanocortin locus in fat accumulation, a study by Wang and colleagues [72] 
cleverly uses a genetic mouse model carrying a proopiomelanocortin-neuron-specific 
knockout of Mecp2, a major epigenetic regulator that acts by binding directly to methylated 
DNA. MECP2 is a known antagonist of SP1-activated transcription [73], therefore as 
expected, the Mecp2−/− mouse model exhibited increased food intake and subsequent 
increased fat mass, which was linked to increased DNA methylation at the 
proopiomelanocortin promoter and decreased proopiomelanocortin expression [72]. This 
finding highlights the importance of methylation status at the SP1 binding site in regulating 
proopiomelanocortin expression required for downstream phenotypic effects.
The hypothalamus utilizes a self-regulating mechanism of energy homeostasis, which relies 
on plasticity of the adaptive neuron in the feeding circuitry and requires rapid cell-to-cell 
interactions [74]. Cell-surface protein polysialylation is critical for modulating synaptic 
adaptation for neural cells [75]. High fat diet in the mouse induces recruitment of histone 
lysine acetyltransferase 8 to activate transcription of polysialylation gene ST8 alpha-N-
acetyl-neuraminide alpha-2,8-sialyltransferase 4 (St8sia4) in hypothalamus. This signal 
promotes the plasticity of proopiomelanocortin neuron in acutely responding to high fat diet 
in mouse [76, 77]. Upregulation of polyasialytion through histone acetylation partially 
offsets the effect of proopiomelanocortin hypermethylation caused by high fat diet. Histone 
lysine acetyltransferase 8 silencing in adult mice leads to accelerated weight gain in 
response to a high fat diet [76]. The diet induced antagonistic changes between 
proopiomelanocortin neuron plasticity and proopiomelanocortin expression demonstrates a 
self-regulatory mechanism for weight control achieved though distinct epigenetic 
machineries.
The role of miRNA in neuronal control of energy homeostasis is still poorly understood. 
However in a recent study, a conditional deletion of Dicer1 (encodes the endoribonuclease 
required for generating mature miRNA) specifically in mouse forebrain neurons results in 
severe hyperphagic obesity, and decreased proopiomelanocortin mRNA in the hypothalamus 
[78]. Further investigation shows that this phenotype occurs likely via upregulation of the 
PI3K–Akt-mTOR pathway. Downregulation of this pathway attenuates adiposity in the 
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Dicer1 knockout mice. The authors used the miTALOS tool to identify miRNA that were 
most likely to play a role in the observed phenotype based on high expression in the 
hypothalamus and predicted targets within the PI3K–Akt-mTOR pathway[79]. Depletion of 
miR-103 was shown to upregulate the pathway while injection of excess miR-103 mimic 
into the arcuate nucleus was shown to reduce body weight changes, food intake and 
expression levels of the gene encoding for catalytic gamma polypeptide of 
phosphoinositide-3 kinase (Pik3cg) within the PI3K–Akt-mTOR pathway [78]. Whether 
there are direct links specifically between miR-103 and proopiomelanocortin remains 
unclear.
2.1.2 Adipose leptin signaling in homeostasis circuitry
Leptin serves as a direct signal from white adipose tissue to the neural network, allowing the 
brain to sense stored nutrients and thus regulate energy homeostasis [80]. Surprisingly, 
elevated serum leptin is usually positively correlated with obesity despite leptin being an 
appetite suppressant and thus anti-obesity hormone [81]. Diet-induced obesity models 
demonstrate that the elevated leptin signals in obesity states is actually due to leptin 
resistance in obese subjects and that the pathway is only upregulated as a means of 
compensating for this resistant phenotype [82]. Both appetite-promoting (orexigenic) 
peptides (i.e. neuropeptide Y (NPY)) and appetite-inhibitory (anorexigenic) peptides (i.e. 
proopiomelanocortin peptides) are regulated by leptin in order to prevent obesity [83]. For 
example, subcutaneous injections of leptin in humans [84]and mice [85] with genetic leptin 
deficiency leads to reduced food intake, fat mass and body weight. This is partly because 
leptin administration activates proopiomelanocortin neurons in the hypothalamus via leptin 
receptor and consequently reduces body weight by inhibiting food intake [81]. Leptin 
signaling in the hypothalamus proopiomelanocortin neurons depends on the nerve growth 
factor Nur77, which subsequently activates signal transducer and activator of transcription 3 
(Stat3) [86]. The downstream STAT3-activated nescient helix-loop-helix 2 in leptin 
signaling pathway is required for transcriptional activation of proopiomelanocortin 
processing enzyme proprotein convertase 1 [87]. Most importantly, STAT3 binds to the cis-
regulatory elements on proopiomelanocortin promoter together with SP1 to activate its 
transcription and diet-induced leptin resistance was usually associated with impaired STAT3 
signaling cascade in proopiomelanocortin neurons [66, 88, 89].
Evidence suggests that leptin signaling pathway from adipose tissue is regulated by 
epigenetic mechanisms. Rhett syndrome patients that carry loss of function mutation in 
Mecp2 exhibit increased plasma leptin concentration [90]. Furthermore, knockout of Mecp2 
in hypothalamic Sim1-expressing neurons elicits hyperphagic and obese phenotypes in mice, 
with increased serum leptin concentration [91]. Meanwhile, knockout of the de novo DNA 
methyltransferase 3 (Dnmt3a) in the mouse hypothalamus caused obesity, increased food 
intake and higher plasma leptin levels [92]. Diet-induced obesity models demonstrate the 
role of epigenetic modulators in controlling leptin function in adipose tissue. DNA 
methylation at the leptin promoter regulates transcription in a complex way. Maternal high 
fat diet is associated with leptin promoter hypomethylation [93]. Interestingly, this effect is 
similar to that of maternal undernourishment, which causes 11 CpGs in the leptin promoter 
to become hypomethylated [94]. However, serum leptin level was oppositely regulated by 
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maternal high fat diet and undernourishment, with the prior model having increased serum 
leptin [93, 94]. The seemingly contradictory observation is consistent with another study 
from Shen and colleagues [95]. Using a diet-induced-obesity model, they show that obesity 
induces adipocyte leptin mRNA levels despite seemingly enriched repressive epigenetic 
states at the leptin promoter, including enriched binding of DNMT1 and methyl-CpG 
binding domain protein 2 (MBD2) and reduced enrichment of the active acetylated histone 
marks and RNA polymerase II at the promoter. In the same study, DNA methylation at the 
leptin promoter was positively correlated with leptin mRNA level in adipose tissue of diet-
induced obese mice, whereas the correlation remained negative in the control [95]. Most 
likely, leptin mRNA quantity is not only determined by rate of transcription, but also, in this 
case, substantially affected by mRNA turnover influenced by dietary compounds such as 
protein and sugar [96]. High fat and sugar diet in rat models induced hypo- and 
hypermethylation of several CpGs in adipocyte leptin promoter. These changes were 
reversible at some of the CpGs by switching to regular diet [97]. Overall, these findings 
demonstrate that when animals are fed an obesogenic diet, adipocyte leptin transcription is 
inhibited primarily through leptin promoter hypermethylation. However, an added effect of 
reduced leptin mRNA turnover may actually cause accumulation of cellular leptin 
transcripts. On the other hand, hypermethylation of hypothalamus proopiomelanocortin 
promoter blocks transcriptional activation by trans-acting factors STAT3 and SP1, thus 
elevating circulating leptin levels. In this manner, diet-induced epigenetic changes can lead 
to increased caloric intake despite high leptin levels.
MiRNA play a significant role in leptin pathways. Hyperphagic obesity caused by deletion 
of Dicer1 (discussed above) is correlated with increased plasma leptin levels [78]. In a 
separate study, Viesti and colleagues [100] investigated the role of miRNAs in increased 
leptin in subcutaneous fat of obese human participants compared to non-obese fat. Although 
there was not a significant correlation between leptin levels and any of the miRNAs 
measured in this study, they reported that higher levels of leptin receptor in obese 
individuals was correlated with lower levels of MiR-145. Interestingly, a separate study 
using mouse models showed increased levels of both MiR-145 and genetically linked and 
co-expressed miR-143 in the liver in response to obesity induced by either high fat or 
genetic mutation (loss-of-function mutation in leptin receptor, db/db) [101]. In the leptin 
receptor mutant samples, MiR-145 was increased compared to controls in liver, skeletal 
muscle and pancreas while miR-143 was increased in heart and pancreas but decreased in 
white adipose tissue. MiR-145 levels measured in white and brown adipose tissue of the 
leptin receptor mutant were not significantly different. Conditional overexpression of 
miR-143 in the liver did not affect body weight or plasma leptin levels but did result in 
impaired glucose tolerance and insulin sensitivity. Similarly overexpressed miR-145 did not 
affect body weight, plasma leptin levels, glucose or insulin pathways [101]. These findings 
demonstrate that up or downregulation of miRNAs found to be associated with obesity and 
obesity-related molecular pathways may not be sufficient to cause obesity or may require 
tissue- or temporal-specificity to exert effect on adiposity.
Several rodent models demonstrate that MiR-200a is also very important for proper leptin 
signaling. Benoit and colleagues reported that compared to untreated controls, rats treated 
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with a leptin inhibitor during postnatal development exhibited higher weight in addition to 
leptin and insulin resistance in the hypothalamus during adulthood [102]. MiR-200a was 
among 34 miRNAs upregulated in the leptin inhibited hypothalamus. Using a leptin 
deficient genetic mouse model of obesity, Crepin and colleagues demonstrated that reduced 
leptin levels in the hypothalamus of deficient animals resulted in up-regulation of miR-200a, 
miR-200b and miR-429 [103]. Leptin treatment in these animals resulted in downregulation 
of these miRNAs, upregulation of the leptin receptor, reduction in body weight and 
restoration of insulin sensitivity. Overexpression of the miR-200a precursor in a 
neuroblastoma cell line impaired insulin and leptin signaling suggesting that changes in this 
miRNA level are sufficient to induce obesity-related metabolic pathways. A separate study 
showed that the correlation between obesity, miR-200a, and leptin is timing dependent 
[104]. When compared to control fed rats, rats fed a high fat diet (45% fat) post weaning 
showed reduced levels of hypothalamic miR-200a after two weeks on the diet and also after 
1 month but this difference was alleviated by 3 months on the diet. Opposite but similar time 
dependent changes were observed with other miRNAs assayed. For example, miR-132 and 
MiR-145 exhibited minimal differences between high fat and control diet at 2 weeks and 1 
month but significant upregulation was observed at 3 months. The authors used the 
ingenuity pathway analysis software to demonstrate that several of the miRNA affected 
were interrelated with each other and genes related to insulin, leptin and adiponectin 
signaling. Of importance, treatment with leptin by IP injection over a 48hr period resulted in 
a significant decrease of MiR-145 and miR-132 compared to untreated animals and the 
effect was exacerbated by fasting. MiR-200a was also seemingly downregulated in leptin 
treated animals but results were not significantly different. MiR-200a is implicated in 
several types of cancer, however, its direct role in leptin signaling remains under 
investigation. MiR-132 was previously implicated in glucose homeostasis in isolated rodent 
and human islets[105] and has been shown to be differentially expressed in both visceral fat 
and whole blood between obese and non-obese human participants [106].
There are very few human studies investigating epigenetic mechanisms regulating the leptin 
pathway. One study of importance shows that in comparing human subjects in weight 
management programs, weight loss response was correlated with adipose leptin mRNA level 
and DNA methylation at non-leptin loci [98]. Leptin was not reported among these 
epigenetically perturbed loci, however, they did include imprinted genes and genes 
associated with body weight and insulin secretion. Changes at these genes were sufficient to 
distinguish low and high responders among overweight and obese human subjects. In 
another study, female subjects with baseline hypomethylation at adipocyte leptin promoter, 
showed better weight loss response to low-calorie diet, though leptin mRNA levels did not 
differ [99]. We can use what has been characterized in the animal models to further 
characterize these responses in humans.
2.1.3 DNA methylation in dopamine neurons in regulating reward circuitry
Food intake is primarily controlled by two subdivisions of the brain: hypothalamus regulates 
homeostatic needs for food, and central reward circuitry (projection from ventral tegmental 
area and substantia nigra to striatum, nucleus accumbens and prefrontal cortex) regulates 
hedonic eating behaviors [83, 107, 108]. While leptin signaling influences 
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proopiomelanocortin and NPY neurons in the hypothalamus for maintaining energy 
homeostasis, dopamine neurons within the mesocorticolimbic system are major regulators of 
the reward pathway [109]. To be noted, hypothalamus dopamine signaling is a regulator of 
energy homeostasis [110]. Obesity is linked to compulsive eating and defective dopamine 
system [111, 112]. Tyrosine hydroxylase is the rate-limiting enzyme in synthesizing 
dopamine [113], and dopamine transporter solute carrier family 6 (SLC6A3) is essential for 
re-absorbing dopamine from synaptic cleft. Two families of dopamine receptors (D1 like 
and D2 like) differ with each other in function and brain distribution [114].
Mice on prolonged high fat diet showed differential regulation of tyrosine hydroxylase and 
dopamine transporter in hypothalamus and ventral tegmental area: transcription of both were 
down-regulated in ventral tegmental area with increased level of promoter DNA 
methylation, while opposite changes of mRNA levels and DNA methylation were observed 
in hypothalamus [107]. Lack of DNMT3A in mouse hypothalamic neuron cells showed 
similar epigenetic alteration with high fat diet on tyrosine hydroxylase promoter 
methylation, suggesting a role of DNMT3A in maintaining dopamine function in 
hypothalamus [92]. The findings indicate concomitant obesogenic epigenetic changes by 
high fat diet in one of the two pathways controlling food intake, which promotes 
homeostatic eating despite lowered desire for palatability. A maternal high fat diet mouse 
model [115] showed more severe obesogenic changes in brain, where both homeostatic and 
hedonic eating are increased with hypomethylation in dopamine transporter but not tyrosine 
hydroxylase promoter. In contrast, a maternal protein restriction model revealed a slightly 
different epigenetic and reward-response change in brain. Tyrosine hydroxylase and 
dopamine transporter were overexpressed in all brain regions including ventral tegmental 
area and hypothalamus, and the dopaminergic neuron developmental regulator cyclin-
dependent kinase inhibitor 1C underwent ~50% decrease in DNA methylation in its 
promoter region with consistent increase in expression throughout the brain [116]. The 
differential regulation of dopamine-associated genes indicates that epigenetic changes 
depend on timing of dietary perturbation and the function of the targeted pathway.
Overall, in the reward circuitry, tyrosine hydroxylase functions to generate dopamine and 
dopamine transporter functions to remove dopamine from synapse to quench the signal. In 
this way, tyrosine hydroxylase and dopamine transporter regulate hedonic eating behaviors. 
To further understand the differences in diet-induced epigenetic changes in tyrosine 
hydroxylase and dopamine transporter promoters, the role of dopamine receptors should be 
investigated. The distinct distribution of dopamine receptors in the brain partially determines 
the role of dopamine in each regions of the brain, as D1 like (D1 and D5) and D2 like (D2, 
D3 and D4) receptors induce opposite intracellular signal transduction cascades [114]. D1 
[117], D2 and D4 [118] receptors are differentially regulated by diets high in fat and/or 
sugar. Interestingly, the effects differ between obesity-prone and -resistant animals. D2 
receptor in reward circuitry was down regulated in obese rat. Also, D2 knockdown 
exacerbated diet-induced deficits in rewards system and increased animals’ desire for 
palatable food [111]. Since dopamine receptors are essential for transmitting dopamine 
signals to the receiving cells, the dopamine -induced intracellular cascade determines the 
outcome of dopamine signaling. However, mechanisms that directly regulate dopamine 
receptors have not been reported.
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2.1.4 Adipose tissue differentiation and fat accumulation
Adipogenesis in adipose tissue is controlled by a variety of transcription regulators, 
primarily the CCAAT enhancer-binding protein (C/EBP) family and the nuclear receptor 
peroxisome proliferator-activated receptor gamma (PPARG) [119]. The extent of fat 
accumulation in white adipose tissue is positively correlated with the adipose expression of 
fatty acid synthase [120], the promoter of which is collectively bound and regulated by 
transcriptional regulators, sterol regulatory element binding transcription factor 1 (SREBF1) 
and other factors [121]. Adipocyte fatty acid synthase also contributes to development of 
diet-induced obesity through PPARG-mediated adipogenesis [122]. Adiposity regulated by 
fatty acid synthase as well as abovementioned transcription factors is influenced by dietary 
compounds including folate [32], Vitamin D [123, 124], Vitamin A [30] and obesogenic 
diets [125].
Histone methylation exerts a critical role for preadipocyte differentiation through marking 
PPARG promoter state as reviewed by Okamura et. al [29]. Epigenetic regulation of PPARG 
and CCAAT/enhancer binding protein (C/EBP) alpha (CEBPA) involves many different 
histone modifiers during different stages of adipogenesis. Pparg promoter is subject to 
bivalent histone modification with concurrent localization of H3K4me3 and H3K27me3 in 
embryonic fibroblasts [126]. Upon adipocyte differentiation, fundamental changes in 
chromatin state occur at the Pparg promoter that are determined by H3K4 
methyltransferases MLL3 and MLL4 [127], PAX interacting (with transcription-activation 
domain) protein 1 (PAXIP1) [128] and the H3K27 demethylase KDM6A [129]. 
Furthermore, PPARG mediates adiposity by regulating the H4K20 mono-methyltransferase 
Setd8 [28] and possibly in a feedback loop mechanism [29]. Genome-wide analysis reveals 
that the majority of PPARG targets during adipogesis are also bound by CEBPA in mouse 
preadipocyte 3T3-L1 [130]. It is noteworthy that PPARG and CEBPA are mutually 
stimulating [29] and both are repressed by the H3K9 tri-methyltransferase the suppressor of 
variegation 3–9 homolog 1 (SUV39H1) in early stages of adipogenesis [131]. C/EBP 
families including CEBPA are required for inducing expression of SREBF1 in maturing 
adipocytes [132] and linking PPARG/C/EBP mediated adiposity to fatty acid synthase 
dependent fat accumulation. Human adipose tissues of obese subjects consistently have 
higher fatty acid synthase mRNA and protein levels in visceral and subcutaneous fat tissue 
[120].
PPARG determines adipogenesis by regulating two histone methyltransferases Setdbl and 
Setd8, which generate repressive histone marks H3K9me3 and active H3K20 methylation 
marks, respectively. Both diet-induced obese and genetically predisposed obese mouse 
models exhibit decreased Setdbl and increased Setd8 mRNA in visceral fat [28]. To be 
noted, PPARG itself and CEBPA are targeted by SETD8 for H4K20me1 -marked activation, 
indicating a potential positive feedback loop for PPARG and its downstream adipogenic 
targets, including its brown adipose tissue isoform [28]. PPARG forms a heterodimer with 
RXRs to bind to promoters and activate transcription. Retinoic acid, an active vitamin A 
derivative, triggers cellular signal cascade via RXRs. Mice on a vitamin A deficient diet 
exhibit elevated adiposity and increased adipose Pparg, Srebfl and Cebpa mRNA levels 
[30]. Last but not least, in a chicken preadipocyte model, interactions between PPARG, 
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CEBPA and fatty acid synthase are epigenetically influenced by folate such that Cebpa 
promoter undergoes hypomethylation upon folate depletion [32].
MiR-27a and miR-27b have been specifically implicated in adipogenesis. In a comparison of 
obese and non-obese participants, miR27a was shown to be significantly upregulated in the 
visceral fat of obese individuals [100]. Kang et al used adipose-derived stem cells to 
demonstrate that adipocyte differentiation triggers the down regulation of prohibitin, 
miR-27a and miR– 27b [137]. In agreement with previous reports [138], the authors showed 
that overexpression of miR-27a and miR-27b inhibits adipocyte differentiation. In addition, 
by using a luciferase reporter assay they demonstrated that the function of miR-27a and 
miR-27b in adipocyte differentiation is partly mediated by a direct interaction with 
prohibitin and subsequent impairment of mitochondrial function. The same research group 
previously demonstrated that prohibitin silencing induces downregulation of mouse Pparg 
[139]. However, a separate study used a luciferase reporter assay in HeLa cells to show that 
miR-27a targets human PPARG 3’UTR to negatively regulate its transcription and that 
overexpression of miR-27a in mouse preadipocytes can inhibit adipocyte differentiation by 
repressing Pparg expression[140]. In addition, miR-27a levels were lower in mature 
adipocytes of high fat diet induced obese mice compared to lean mice.
2.1.5 NNMT drains methyl donor pool and regulates energy expenditure
Nicotinamide N-methyltransferase (NNMT) catalyzes N-methylation of nicotinamide using 
S-adenosyl-L-methionine (SAM) and yields 1-methylnicotinamide and S-adenosyl-L-
homocysteine (SAH). Extensive studies link NNMT function to Parkinson’s disease [141], 
hyperhomocysteinemia [142], cancer [143, 144], insulin resistance [145, 146] and obesity 
[147]. NNMT activity in white adipose tissue is upregulated by high fat diet while not 
affected in liver, despite that NNMT was primarily expressed in liver [142]. This indicates a 
role of adipose NNMT in diet-induced obesity. Emerging evidence suggests that NNMT 
contributes to increased risk for insulin resistance and type 2 diabetes associated with 
visceral adiposity [146].
Elevated NNMT activity leads to depletion of SAM, the donor of methyl groups for DNA 
and histone methylation. Decreased availability of methyl group can potentially directly 
affect epigenetic pathways. Indeed, maternal supplementation of the NNMT substrate 
nicotinomide induced global hypomethylation in both placenta and fetal liver, which was 
prevented by co-supplementation of the methyl donor nutrient betaine [31]. Induction of 
NNMT in cancer cells results in global H3K9 and H3K27 hypomethylation. These defective 
histone marks were restored upon Nnmt knockdown [143].
Kraus and colleagues demonstrated that Nnmt knockdown in white adipose tissue and liver 
protects against diet-induced obesity and insulin resistance in mice. The leanness was caused 
by elevated energy expenditure rather than changes in food intake [147]. Polyamine flux 
contributes to energy expenditure and SAM provides the starting materials for this pathway 
after removal of methyl groups. Ornithine decarboxylase and spermidine-spermine N-
acetyltransferase are rate-limiting enzymes in polyamine metabolism [148]. In the diet-
induced obesity model, Nnmt knockdown activated expression of ornithine decarboxylase 
and spermidine-spermine N-acetyltransferase as well as polyamine flux in white adipose 
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tissue through increasing global H3K4me1/2/3 levels. In adipocyte cell culture, enrichment 
of methylated H3K4 was increased at ornithine decarboxylase and spermidine-spermine N-
acetyltransferase genes upon NNMT inhibition [147]. NNMT is also involved in 
development of insulin resistance and type 2 diabetes as demonstrated in glucose transporter 
type 4 (Glut4) knock-out and overexpressed, and genetically predisposed diabetic (db/db) 
mouse models, where white adipocyte Nnmt was upregulated in diabetic conditions [147]. 
Treatments containing niacin were reported to trigger insulin resistance in patients with 
hyperlipidemia [149, 150], however the mechanisms are still unknown. The widespread 
effects of NNMT on epigenetic pathways may serve as a tentative explanation for insulin 
resistance caused by niacin (and its derivatives nicotinamide and nicotinic acid) usage, 
although further investigation is required.
2.2. Role of environmental toxicants in nutrient-regulated obesity pathways
2.2.1 BisphenolA (BPA)
BPA is an endocrine disrupting compound (EDC) found in many commonly used products 
and thus a majority of the world’s population is exposed to varying levels [151, 152]. A 
critical breakthrough in understanding nutrient-toxicant interactions was established through 
a study published by Dolinoy and colleagues in 2007 [153] showing that perturbation of 
mouse coat color induced by Bisphenol A (BPA) exposure is rescued by methyl donor 
nutrient supplementation (folic acid, choline, betaine and vitamin B12). This was not the 
first demonstration of dietary intervention as a means of alleviating toxicant effects. 
However, this was the first demonstration of the role of epigenetic state (DNA methylation) 
at the agouti viable yellow (Avy) locus as the intermediate link between toxicant exposure, 
diet and phenotypic outcome. The mechanism of epigenetic rescue by methyl donor 
nutrients remains unclear but has been shown to occur in several other studies [154–157]. 
The commonly accepted paradigm is that methyl donor nutrient intake determines the 
availability of subsequent methyl groups generated through the one carbon metabolism 
pathway.
Recent studies link BPA to obesity through several different mechanisms [158, 159]. Cell 
culture studies show that BPA at concentrations >10uM increases murine adipocyte 
differentiation and decreases global DNA methylation compared to controls [160]. Mackay 
and colleagues [161] recently used a CD-1 mouse model to show that maternal consumption 
of a maximum of 7.2 µg/kg/day on average of BPA (well below the EPA reference dose of 
50µg/kg/dy) resulted in higher weight of both male and female offspring. Significantly 
higher caloric intake was observed in female offspring only while the males exhibited 
greater energy expenditure. Although BPA treated female offspring had increased plasma 
leptin levels, males were unaffected. Also, in BPA-exposed female offspring there was no 
increased proopiomelanocortin expression in the arcuate nucleus, which normally would 
have signalled excess energy, satiety and subsequent reduced food intake. Interestingly, 
most of these effects of BPA were only observed when mice were exposed in conjunction 
with a high fat diet, demonstrating the aggregate effect of diet. The sexually dimorphic 
nature of these effects is likely due to the estrogenic properties of BPA. Indeed, females but 
not males, exposed to BPA exhibited increased estrogen receptor alpha (ERα) mRNA 
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expression in the hypothalamus compared to controls. As a potential mechanism, a separate 
study shows that in utero BPA exposure alters methylation status at ERα and ERβ[162].
BPA exposure has also been linked to epigenetic perturbation at imprinted loci in the mouse 
[163]. Of particular interest, Susiarjo and colleagues reported that maternal BPA exposure 
during pregestation, gestation and lactation at a dose of 10mg/kg/day results in a gain of 
methylation at the DMR1 of the Igf2 gene. This was correlated with loss of imprinted 
monoallelic expression of Igf2 and Igf2 overexpression. A follow up study showed that these 
epigenetic changes coincide with increased body fat, insulin resistance and glucose 
intolerance only in adult male offspring [164]. In contrast to the study by Mackay and 
colleagues described above [161], females were seemingly unaffected. Interestingly, F2 
male offspring inherited the increase in Igf2 expression and Igf2 DMR1 methylation changes 
as well as the metabolic phenotypes from their sires. Use of a targeted genetic mutant mouse 
model, H193.8/+ mice [165], showed that of loss of Igf2 imprinting and overexpression is 
sufficient to result in glucose intolerance phenotype in the male but not female mice. These 
gender specific phenotypes may also be linked to the estrogenic properties of BPA as 
speculated above. The explanation for the opposite nature of the gender bias in the two 
studies remains unclear although it is well known that BPA does not always have a linear 
dose response curve and the difference may be explained by amount and timing of dosage.
2.2.2 Alcohol
Fetal alcohol exposure is linked to increased feeding behaviors and obesity in childhood 
[166, 167]. As discussed above, proopiomelanocortin promoter methylation regulates 
proopiomelanocortin expression and increased proopiomelanocortin promoter methylation is 
linked to obesity. Fetal alcohol exposure in a rat model results in proopiomelanocortin 
promoter hypermethylation and downregulated proopiomelanocortin expression in the 
hypothalamus persisting until the F3 generation [168]. Surprisingly, these changes were not 
correlated with weight differences as has been shown in dietary models of perturbed 
proopiomelanocortin [169]. Further assessment by the same research group revealed that 
alcohol-induced proopiomelanocortin repression is alleviated by dietary choline 
supplementation during gestation [157]. Based on this finding, the authors propose that 
alcohol-induced methylation changes at proopiomelanocortin likely involve disruption of the 
one carbon metabolism pathway and subsequent limitation of methyl groups. In this way, 
choline may rescue by increasing methyl group availability thus compensating for alcohol-
induced disruption of folate-derived methyl groups [157]. However, this “limited methyl 
group” hypothesis is contradicted by the apparent gain of methylation induced by alcohol at 
the proopiomelanocortin promoter and choline-induced hypomethylation required for 
restoration of gene expression. Therefore, the mechanism of alcohol-induced 
proopiomelanocortin promoter hypermethylation and the choline dependent rescue is likely 
via a separate or indirect pathway.
More evidence of an indirect role comes in a recent study by the same group showing that 
fetal alcohol exposure in rats increases MECP2 levels and MECP2 binding to the 
proopiomelanocortin locus in the hypothalamus [170]. Mecp2 knockdown via targeted 
shRNA to the brain alleviated the effects of fetal alcohol exposure on proopiomelanocortin 
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expression in the hypothalamus. We can speculate that the increased MECP2 binding at the 
proopiomelanocortin promoter is the result of a combination of hypermethylation at the 
proopiomelanocortin promoter and increased MECP2 protein availability leading to 
increased recruitment of MECP2 to the locus and increased proopiomelanocortin repression. 
The mechanistic link between choline supplementation and the effects of MECP2 remains 
unclear, however, several studies show that choline supplementation also effectively rescues 
some of the phenotypic and molecular effects associated with Mecp2 depletion in Rhett 
syndrome models [171–173]. All together these finding suggest a complex diametric role for 
choline in MECP2 mediated epigenetic mechanisms such that choline supplementation 
appears to rescue the effects of both Mecp2 depletion and overexpression.
2.2.3 Persistent organic pollutants
Persistent organic pollutants (POPs) are classified on the basis of having slow degradation 
process such that they persist in a toxic form in the environment or body in a way that may 
lead to accumulating and/or chronic exposure. These man-made compounds are either 
synthesized or result as a byproduct of industrial processing. Many POPs have also been 
classified as endocrine disruptors [174, 175]. A recent study showed that metabolically 
abnormal obese individuals have higher levels of POPs in plasma compared to metabolically 
healthy obese individuals [176]. Obesity is primarily classified based on body mass index 
(BMI) or waist to hip circumference ratio. However, many individuals that surpass the 
obesity threshold set for these parameters do not exhibit the altered metabolic state linked to 
increased risk for obesity related diseases such as diabetes and CVD. Taken together with 
these new findings, it is possible that for some individuals “obesity” status alone may not 
pose the extended disease risk assumed and additional factors are required to result in 
disease-related metabolic state. New studies allow us to speculate that the propensity for 
abnormal metabolic state associated with obesity may be influenced by POPs. Thus 
evaluating the extent of environmental pollutant exposure may be of importance in linking 
obesity to further metabolic disruption. Further detailed in vivo studies need to be done to 
determine the involvement of epigenetic mechanisms influencing the role of POPs in 
obesity. Cell culture studies show that POPs such as 2,2’,4,4’-tetrabrominated diphenyl ether 
(BDE-47) and tributyltin (TBT) at concentrations of 2.5–25uM and ≥10nM, respectively, 
increase murine adipocyte differentiation compared to controls [160]. Furthermore, BDE-47 
exposure but not TBT exposure was linked to decreased global methylation. A more recent 
study with similar results showed the increase in adipocyte differentiation caused by TBT 
exposure is linked to the PPARG signaling pathway for which we have discussed various 
pathways of epigenetic regulation [177].
3. Conclusions
In Table 1, we provide a compilation of epigenetic mechanisms acting within several major 
molecular pathways of obesity. Taken together, we show that many of the perturbed 
epigenetic mechanisms are consistent between model organisms with supportive human 
subject data; between nutrient and toxicant models; and are supported by genetic models of 
disrupted epigenetic regulators. Nevertheless, many of these findings are only correlative 
and we conclude that much more research is required to fully understand the role of such 
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perturbations in obesity; to determine whether these changes are stable or change further 
with progression of obesity and its related diseases; and to determine whether different types 
of metabolic syndromes are associated with specific epigenetic profiles, pathway 
dysregulation or linked to a particular environmental stimulus (i.e. diet, toxicant etc.). 
Studies to determine whether such epigenetic defects are reversible and the agents that 
reverse them will likely identify potential targets for diagnosis and treatment of obesity and 
obesity-related disease.
Figure 1 illustrates our current knowledge of some of the links between epigenetic 
mechanisms and molecular pathways of obesity including (1) homeostatic and hedonic 
eating behaviors controlled by brain and adipocyte-derived hormones, (2) adipocyte 
differentiation and fat accumulation, and (3) energy expenditure. This evidence of epigenetic 
dysregulation of molecular pathways of obesity supports the role on non-caloric mechanism 
of obesity, and further negates the paradigm that obesity is a disease caused merely by 
excess caloric intake. Epigenetic mechanisms can explain how both the source of fat and 
proportion of fat, even in an isocaloric diet can effect epigenetic mechanisms and lead to 
disruption of energy homeostatis via molecular pathways. For example, a recent study 
demonstrates that an isocaloric high fat diet in a rat model results in significantly increased 
body weight and fat mass, which is linked to hypomethylation upstream of the fatty acid 
synthase promoter (within a region from −700 to −1100 bp from the transcription start site) 
and decreased adipose fatty acid synthase mRNA levels and [136]. This suggests that in 
epigenetically-induced obesity, the proportion of fat in the diet may be more important in 
some contexts than the total amount of calories.
Interestingly, our comparison of nutrient and toxicant exposure models indicates that similar 
epigenetic and molecular effects may have varied phenotypic outcomes. For example in the 
alcohol model discussed above there is no change in weight although DNA 
hypermethylation at the proopiomelanocortin promoter is detected as well as decreased 
proopiomelanocortin expression, a molecular effect linked to increased weight gain in the 
dietary models [170]. This finding indicates that although proopiomelanocortin expression 
plays a critical role in weight, either mRNA repression alone is not sufficient to result in 
weight gain or the levels induced by alcohol exposure in this model did not cross the 
threshold required to manifest the phenotype. Thus it is important to point out that changes 
in DNA methylation, even when coinciding with gene expression changes, may not result in 
altered phenotypic outcome. The implications are that use of epigenetic states as biomarkers 
of diseases such as obesity require careful determination of correlation with both gene 
expression and phenotypic outcome. Moreover, this brings to question whether gene dosage 
thresholds should be more carefully considered in determining the role of molecular changes 
in phenotypic outcomes.
Another potential factor contributing to discrepancies between exposure outcomes is the 
timing of exposure or the timing of molecular perturbation in the pathway of interest. These 
are not necessarily mutually inclusive. For example, when challenged by high fat diet, the 
length of BPA exposure during gestation resulted in differing phenotypic outcome. Adult 
male offspring from a maternal diet containing a maximum of 7.2 µg/kg/day BPA 
throughout gestation and lactation showed no change in caloric intake compared to 
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unexposed controls [161], while those maternal BPA exposure at a dose of 10 µg/kg/day 
from gestational day 9 to 16 demonstrated greater caloric intake [178]. Timing of 
environmental exposure may target different windows of susceptibility. This is relevant for 
treatments performed at different stages of development (i.e. embryonic vs adult); different 
parental routes of exposure (maternal vs. paternal); and different timing of parental exposure 
(i.e. pre-gestation, gestation, lactation). In particular, in utero exposure effects will likely 
differ from adult exposure since fetal somatic tissues and germ cells are undergoing major 
epigenetic programming [179]. Importantly, in the case of fetal exposure, effects may not be 
observed until later life stages as in the case of developmental origins of adult disease. 
Another important aspect of timing of epigenetic changes related to obesity is the fact that it 
remains unclear whether obesity always precedes or follows the perturbed epigenetic state. 
Genetic models that act by knocking out/down the key metabolic or epigenetic regulator 
genes suggest that at least some observed initial epigenetic changes precede obesity-related 
phenotypes [72, 91, 92, 147, 170]. These may be potential targets of diagnoses, prevention 
or treatment.
Many cell culture models (including those discussed here) provide useful mechanistic 
information, however, without direct evidence in vivo, phenotypic and disease relevance 
cannot be definitively determined. Also, we cannot rule out other possible causes of 
disparities in cell culture and animal studies, such as uncontrolled exposure to other 
potentially confounding environmental stimuli. For example, epigenetic states at 
proopiomelanocortin are affected by diet, alcohol, POPs and even early life stress [65, 70, 
168–170]. Ibrahim and colleagues [180] showed that POP exposure in mice fed 
contaminated whale meat did not lead to weight gain nor standard metabolic disruption in 
insulin signaling pathways. The authors suggest that the added nutritional components of the 
whale meat may have confounded the data since these mice actually weighed less compared 
to mice fed standard chow and lard based high fat diet.
Importantly, we highlight some overlapping mechanisms of obesity that are influenced by 
both nutrition and environmental toxicants. This area of research requires much more 
attention since clearly both combined play a major role in obesity either having separate or 
aggregate effects. For example, several studies including some discussed here show that the 
obesity-related effects of toxicant exposure are further exacerbated by dietary modulation, 
such as addition of high fat diet [161, 178, 181]. Interestingly, some studies suggest that 
increased adiposity caused by high fat diet may actually provide a protective effect during 
toxicant exposure. For example, exposure to polychlorinated biphenyls (PCB-77) in a mouse 
model has been shown to impair glucose homeostasis via a TNFα dependent pathway only 
when combined with weight loss [182]. This paradigm is supported by the lipophilic nature 
of many POPs allowing for sequestration in adipose tissue and thus limiting the potential 
adverse effects of circulation in the body. A separate study by the same group demonstrated 
rescue of PCB-induced impaired glucose homeostasis after treatment with resveratrol, a 
polyphenol found in many types of berries that has previously been shown to inhibit 
inflammatory cytokines such as TNFα [183]. Likewise is the case of rescue of alcohol-
induced epigenetic changes by choline supplementation [157]. Thus characterization of 
overlapping mechanisms will clarify the potential for use of nutrition in the treatment of 
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toxicant-induced obesity. Furthermore, by characterizing this complex phenotype through 
multiple approaches including nutrient, toxicant and genetic models, we will likely elucidate 
novel parts of the pathways involved while obtaining certainty of previously established 
mechanisms. However, it should be noted that in order to accurately compare the effects of 
diet vs toxicant or combined exposures there is a need for some level of standardized 
experimental design between projects and more controlled environment in order to allow for 
comparison.
A significant amount of progress has been made in determining the role of non-coding RNA 
in epigenetic mechanisms of obesity. In particular, as discussed above, miRNA have been 
repeatedly shown to be significantly associated with both leptin signaling and adipogenesis. 
However, it has remained a great challenge to identify the direct targets of such miRNA 
activity within obesity-related molecular pathways. This is in part due to the fact that 
miRNA-target binding patterns are highly variable and miRNA function is often tissue-
specific [184]. In addition, a single miRNA can have hundreds of targets while multiple 
miRNAs can act coordinately on the same target [185]. It is also a challenge to assay 
differences in precursor species and cellular localization of the miRNA being measured. 
Because of these challenges, many studies rely on measuring the overall cellular levels of 
miRNA as a proxy for activity. Although this is not a direct measure for determining the 
impact on epigenetic activity of the miRNA at the target, it does provide correlative clues to 
potential interactions. Unfortunately, even when miRNA with perturbed expression levels 
are detected, co-regulation of multiple miRNAs due to close genomic proximity or shared 
regulators (i.e. transcription factors) make it difficult to determine which of the miRNA 
identified is causal in a particular pathway. Thus, a significant amount of research remains 
to be done in understanding the role of miRNA and other types of non-coding RNA in 
obesity-related phenotypes. We have not really even begun to dissect the role of nutrition 
and other environmental factors such as toxicants in perturbing non-coding RNA function 
with regards to obesity-related pathways.
Although there are ever increasing improvements in the types of technology available to 
assess epigenetic mechanisms, the interpretation of epigenetic findings in terms of biological 
relevance remains a significant challenge. This is in part due to the complexity of epigenetic 
mechanisms and the gaps in our understanding of how multiple epigenetic mechanisms 
work together to regulate gene expression. Epigenetic regulation of fatty acid synthase 
transcription is an excellent example of the complex interaction between epigenetic 
mechanisms and transcriptional machinery required for normal gene expression. In a recent 
study of a high fat diet rat model investigators observed substantial hypomethylation at −90 
bp but also reported hypermethylation at −62 bp at the fatty acid synthase promoter 
correlated with increased fatty acid synthase mRNA level in adipose tissue [125]. To explain 
this differential methylation regulation, the −90bp locus is actually within the binding site of 
NF-Y and SP1 activation complex [133], while the −62bp locus is a binding site of upstream 
regulatory factor [134] and is essential for upstream regulatory factor and SREBF1-induced 
fatty acid synthase expression upon feeding [135]. Thus, even at a single gene promoter, 
contradicting DNA methylation states may be detected and only together explain 
dysregulation of transcription. Understanding which regulatory elements are present within 
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epigenetically regulated regions is critical to understanding the epigenetic mechanisms of 
disruption and hence the biological relevance of changes.
In conclusion, this assessment only further highlights the fact that obesity is a highly 
complex and multifactorial disease. Therefore, we are only just beginning to fit the pieces 
together to define the pathways and modes of perturbation contributed by environmental 
exposure. One factor that likely contributes to mixed results from studies on human obese 
population is the recognition of metabolically normal and abnormal obesity. Approximately, 
half of the obese adults in the US are found to be metabolically normal as measured by 
several cardiometabolic parameters. On the other hand, up to one-fourth of non-obese adults 
are metabolically abnormal and at risk for many of the diseases associated with obesity 
[186]. Interestingly, data shows that metabolically normal obese people are less susceptible 
to certain weight-related phenotypes [187], and are less susceptible to the effects of POPs 
compared to metabolically abnormal counterparts [176]. Thus, inconsistencies and non-
reproducibility of studies on obese population could be attributed to metabolic heterogeneity 
in obese subjects, which underlines the importance of differentiating obese subjects using 
parameters for various metabolic functions.
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Obesity-linked metabolic pathways susceptible to diet induced epigenetic perturbation. 
Hypothalamic proopiomelanocortin neurons control homeostatic eating by expressing 
appetite-inhibitory proopiomelanocortin. Obesogenic diet causes repression of 
proopiomelanocortin, which increases food intake. This is partially offset by acute 
proopiomelanocortin neuron plasticity change via upregulating ST8SIA4 as a feedback-loop. 
Adipose tissue secretes leptin to signal (indicated by pointed arrow) excessive energy 
storage in hypothalamus by upregulating proopiomelanocortin expression. Obesogenic diet 
causes blunted leptin response in proopiomelanocortin neurons and repressed leptin 
transcription in adipocyte. Meanwhile compulsive eating is promoted through diet-induced 
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dysregulation of tyrosine hydroxylase, dopamine transporter and cyclin-dependent kinase 
inhibitor 1C in dopaminergic neurons in central reward circuitry, boosting desire for 
palatable food. Adipocyte differentiation as well as fat accumulation is perturbed by 
nutrition targeting CEBPA, PPARG and fatty acid synthase, causing excessive adiposity. 
Dietary components also influence energy expenditure, represented by regulating ornithine 
decarboxylase and spermidine-spermine N-acetyltransferase in fat and possibly liver through 
NNMT, which acts by inhibiting (indicated by flat-end arrow) the enrichment of H3K4 
methylation at ornithine decarboxylase and spermidine-spermine N-acetyltransferase. WAT: 
white adipose tissue. Epigenetically regulated genes in each metabolic pathway are listed in 
bold and italics (POMC: proopiomelanocortin; ST8SIA4: ST8 alpha-N-acetyl-neuraminide 
alpha-2,8-sialyltransferase 4; TH: tyrosine hydroxylase; SLC6A3: dopamine transporter 
solute carrier family 6; CDKN1C: cyclin-dependent kinase inhibitor 1C; CEBPA: CCAAT/
enhancer binding protein (C/EBP) alpha; PPARG: peroxisome proliferator-activated 
receptor gamma; LEP: leptin; FASN: fatty acid synthase; ODC: ornithine decarboxylase; 
SSAT: spermidine-spermine N-acetyltransferase). Epigenetic regulatory mechanisms are 
depicted for each pathway and include DNA methylation, histone marks and epigenetic 
regulatory genes (NNMT: Nicotinamide N-methyltransferase. SETDB1: SET domain 
bifurcated 1; SETD8: SET domain containing protein 8; MECP2: methyl CpG binding 
protein 2; MBD2: methyl-CpG binding domain protein 2; DNMT1/3A: DNA 
methyltransferase 1/3A; KAT8: lysine acetyltransferase 8).
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